Los GLP-1 tampoco deberan verse como soluciones a corto plazo, dice el editorial
While other reviews have described the MACE risk reduction in the general population with T2DM [23, 24], non-T2DM [25], or both [26], the present study seeks to address the gap in the literature in providing a comprehensive meta-analysis on the number need to treat (NNT), efficacy and safety profile of GLP-1RA in reducing the risk of myocardial infarction (MI) and individual ASCVD constituents, namely non-fatal MI, unstable angina, coronary revascularization, and/or cardiovascular mortality
Its an unregulated vial ordered from the internet
Most patients who microdose take somewhere between 0.05 mg and 0.15 mg weekly, which comes out to roughly a quarter or half of the traditional starting dose
Basal insulin and cardiovascular and other outcomes in dysglycemia